BMO Capital Initiates Coverage On IGM Biosciences With Outperform Rating, Announces Price Target of $21
BMO Capital Initiates IGM Biosciences(IGMS.US) With Buy Rating, Announces Target Price $21
IGM Biosciences Analyst Ratings
Stifel Maintains IGM Biosciences(IGMS.US) With Buy Rating, Raises Target Price to $27
RBC Capital Reaffirms Their Buy Rating on IGM Biosciences (IGMS)
IGM Biosciences Is Maintained at Outperform by RBC Capital
IGM Biosciences Analyst Ratings
Analysts' Top Healthcare Picks: Intuitive Surgical (ISRG), IGM Biosciences (IGMS)
RBC Capital Maintains IGM Biosciences(IGMS.US) With Buy Rating, Raises Target Price to $20
A Quick Look at Today's Ratings for IGM Biosciences(IGMS.US), With a Forecast Between $9 to $25
IGM Biosciences Is Maintained at Outperform by Wedbush
IGM Biosciences Analyst Ratings
A Quick Look at Today's Ratings for IGM Biosciences(IGMS.US), With a Forecast Between $9 to $48
RBC Capital Remains a Buy on IGM Biosciences (IGMS)
IGM Biosciences Downgraded to Underweight From Neutral at JPMorgan
IGM Biosciences: Hold Rating Amidst Strategic Shift and Leadership Changes
Stifel Maintains IGM Biosciences(IGMS.US) With Buy Rating, Announces Target Price $25
Analysts Are Bullish on These Healthcare Stocks: IGM Biosciences (IGMS), 4D Molecular Therapeutics (FDMT)
IGM Biosciences Is Maintained at Neutral by HC Wainwright & Co.
H.C. Wainwright Maintains IGM Biosciences(IGMS.US) With Hold Rating, Cuts Target Price to $11